Academic Cancer Care

Ironwood Cancer & Research Centers are committed to the advancement of medical knowledge and patient care. Medical research has and continues to transform the practice of medicine resulting in a high quality of care we enjoy today. We believe that by supporting clinical research today, we are helping build the future of medicine and the profound developments that are sure to come. We have an active and expanding clinical research program.

We have a comprehensive team of physician investigators, research nurses, clinical research coordinators, research assistants and regulatory specialist serving all our offices. This allows us to provide the option for our eligible patients to the latest therapies and treatments.  If you are interested in participating in a clinical trial, please talk to your physician or call our research department at 480-398-7671.  Learn more about participating in a clinical trial here.

Current Studies at Ironwood Cancer & Research Centers

Cancer Type

A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. (VERITAC-2) ID NCT05654623

Protocol number C4891001

Sponsor Pfizer


Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Hormone Receptor-positive/​Human Epidermal Growth Factor Receptor 2 Negative (HR+/​HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy (ASCENT-07) ID NCT05840211

Protocol number GS-US-598-6168

Sponsor Gilead Sciences


A Study of Camizestrant in ER+/​HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1) ID NCT05774951

Protocol number D8531C00002

Sponsor Astra Zeneca


ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation (ORACLE) ID NCT05059444

Protocol number 02-MX-003

Sponsor Guardant Health, Inc.

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) ID NCT05153239

Protocol number PM1183-C-008-21

Sponsor PharmaMar


Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/​KEYLYNK-013) ID NCT04624204

Protocol number MK7339-013

Sponsor Merck


Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) ID NCT05153239

Protocol number PM1183-C-008-21

Sponsor PharmaMar

A Phase 2 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Patients With Stage 4 Non-Small Cell Lung Cancer ID  NCT06246110

Protocol number EIK1001-005

Sponsor Eikon Therapeutics

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08) ID NCT05215340

Protocol number DS1062-A-U304

Sponsor Daiichi-Sankyo

Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) ID NCT05555732

Protocol number DS1062-A-U303

Sponsor Daiichi-Sankyo

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PACIFIC-8) ID NCT05211895

Protocol number PACIFIC-8 D9075C00001

Sponsor Astra Zeneca

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 ID NCT06003231

Protocol number SGNDV-005

Sponsor Seagen Inc.

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC ID NCT04928846

Protocol number M18-868

Sponsor AbbVie


Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC ID NCT05199818

Protocol number LP-CT-PALO-202101

Sponsor Xiamen LP Pharmaceutical Co., Ltd

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician’s Choice New Hormonal Agents (EvoPAR-PR01) ID NCT06120491

Protocol number D973C00001

Sponsor Astra Zeneca

A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (SUNMO) ID NCT05171647 

Protocol number GO43643_SUNMO

Sponsor Hoffmann-La Roche